Paper Details

  1. Home
  2. Paper Details

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial.

Author: ChungJames B, CollierDavid H, GladmanDafna D, HelliwellPhilip S, KricorianGregory, LiuLyrica, MeasePhilip J, RitchlinChristopher T

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Etanercept monotherapy and combination therapy with etanercept and methotrexate showed greater efficacy than methotrexate monotherapy in patients with psoriatic arthritis (PsA). Combining methotrexate and etanercept did not improve the efficacy of etanercept.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To examine the efficacy of methotrexate monotherapy relative to etanercept monotherapy and the value of combining methotrexate and etanercept for the treatment of patients with psoriatic arthritis (PsA). METHODS: In this double-blind study, 851 patients with PsA were randomized to 1 of 3...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618246/

データ提供：米国国立医学図書館（NLM）

Comparing Etanercept and Methotrexate for Psoriatic Arthritis Treatment

Psoriatic arthritis (PsA) is a chronic inflammatory disease affecting the joints and skin. This research compares the efficacy of etanercept, a tumor necrosis factor (TNF) inhibitor, and methotrexate, a disease-modifying antirheumatic drug (DMARD), as monotherapy and in combination for the treatment of PsA. The study aimed to determine the most effective treatment approach for improving PsA symptoms and slowing disease progression.

Etanercept Shows Superior Efficacy for Psoriatic Arthritis

The study found that etanercept monotherapy demonstrated greater efficacy than methotrexate monotherapy in improving PsA symptoms, reducing disease activity, and slowing radiographic progression. Combining etanercept with methotrexate did not significantly enhance the efficacy of etanercept alone.

Making Informed Decisions About PsA Treatment

This research provides valuable information for healthcare professionals treating patients with PsA. The study highlights the superior efficacy of etanercept compared to methotrexate, suggesting that etanercept could be a preferred treatment option for many patients with PsA.

Dr. Camel's Conclusion

The quest for effective treatments for psoriatic arthritis is like a long and winding desert journey. This research offers a valuable roadmap, revealing the superior efficacy of etanercept compared to methotrexate. The findings provide a clear path for clinicians to navigate the complexities of PsA treatment, ensuring the best possible outcomes for their patients.

Date :
  1. Date Completed 2020-01-06
  2. Date Revised 2020-03-09
Further Info :

Pubmed ID

30747501

DOI: Digital Object Identifier

PMC6618246

Related Literature

Article Analysis
・Effective treatment of psoriatic arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.